Bank of America’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-65,749
| Closed | -$1.9M | – | 6458 |
|
|
2025
Q4 | $1.9M | Sell |
65,749
-648
| -1% | -$12.3K | ﹤0.01% | 4107 |
|
|
2025
Q3 | $515K | Buy |
66,397
+65,594
| +8,169% | +$492K | ﹤0.01% | 5771 |
|
|
2025
Q2 | $5.95K | Sell |
803
-11,772
| -94% | -$103K | ﹤0.01% | 7273 |
|
|
2025
Q1 | $108K | Sell |
12,575
-25,583
| -67% | -$395K | ﹤0.01% | 6455 |
|
|
2024
Q4 | $1.36M | Sell |
38,158
-1,443
| -4% | -$74.6K | ﹤0.01% | 4772 |
|
|
2024
Q3 | $1.87M | Buy |
39,601
+33,210
| +520% | +$1.47M | ﹤0.01% | 4612 |
|
|
2024
Q2 | $321K | Sell |
6,391
-1,992
| -24% | -$144K | ﹤0.01% | 5620 |
|
|
2024
Q1 | $939K | Buy |
8,383
+1,900
| +29% | +$189K | ﹤0.01% | 4967 |
|
|
2023
Q4 | $376K | Buy |
6,483
+1,788
| +38% | +$71.9K | ﹤0.01% | 5700 |
|
|
2023
Q3 | $149K | Sell |
4,695
-7,365
| -61% | -$350K | ﹤0.01% | 6065 |
|
|
2023
Q2 | $992K | Sell |
12,060
-28,575
| -70% | -$4.18M | ﹤0.01% | 4781 |
|
|
2023
Q1 | $4.18M | Buy |
40,635
+10,206
| +34% | +$1.43M | ﹤0.01% | 3690 |
|
|
2022
Q4 | $4.46M | Buy |
30,429
+14,523
| +91% | +$2.45M | ﹤0.01% | 3492 |
|
|
2022
Q3 | $2.69M | Buy |
15,906
+13,635
| +600% | +$2.22M | ﹤0.01% | 4020 |
|
|
2022
Q2 | $262K | Buy |
2,271
+891
| +65% | +$83.8K | ﹤0.01% | 5902 |
|
|
2022
Q1 | $138K | Sell |
1,380
-334
| -19% | -$39K | ﹤0.01% | 6688 |
|
|
2021
Q4 | $266K | Sell |
1,714
-1,381
| -45% | -$269K | ﹤0.01% | 6325 |
|
|
2021
Q3 | $730K | Buy |
3,095
+886
| +40% | +$259K | ﹤0.01% | 5342 |
|
|
2021
Q2 | $750K | Buy |
2,209
+873
| +65% | +$330K | ﹤0.01% | 5128 |
|
|
2021
Q1 | $540K | Sell |
1,336
-13,755
| -91% | -$6.67M | ﹤0.01% | 5295 |
|
|
2020
Q4 | $10M | Sell |
15,091
-8,845
| -37% | -$4.92M | ﹤0.01% | 2477 |
|
|
2020
Q3 | $11.1M | Buy |
23,936
+6,094
| +34% | +$3.08M | ﹤0.01% | 2204 |
|
|
2020
Q2 | $10.4M | Buy |
17,842
+5,772
| +48% | +$1.97M | ﹤0.01% | 2173 |
|
|
2020
Q1 | $1.76M | Buy |
12,070
+10,487
| +662% | +$1.83M | ﹤0.01% | 3580 |
|
|
2019
Q4 | $227K | Sell |
1,583
-42
| -3% | -$3.07K | ﹤0.01% | 5562 |
|
|
2019
Q3 | $64K | Sell |
1,625
-242
| -13% | -$17.6K | ﹤0.01% | 6225 |
|
|
2019
Q2 | $189K | Buy |
1,867
+478
| +34% | +$56.3K | ﹤0.01% | 5669 |
|
|
2019
Q1 | $183K | Buy |
1,389
+117
| +9% | +$14.7K | ﹤0.01% | 5568 |
|
|
2018
Q4 | $129K | Buy |
1,272
+1,188
| +1,414% | +$188K | ﹤0.01% | 5780 |
|
|
2018
Q3 | $21K | Buy |
84
+7
| +9% | +$2.35K | ﹤0.01% | 6495 |
|
|
2018
Q2 | $34K | Sell |
77
-104
| -57% | -$45.6K | ﹤0.01% | 6321 |
|
|
2018
Q1 | $72K | Sell |
181
-183
| -50% | -$72.3K | ﹤0.01% | 5896 |
|
|
2017
Q4 | $150K | Buy |
364
+154
| +73% | +$67.2K | ﹤0.01% | 5549 |
|
|
2017
Q3 | $91K | Buy |
+210
| New | +$82.8K | ﹤0.01% | 5712 |
|
Other funds holding MRSN
Bank of America's MRSN Position: Q1 2026 in Review
Bank of America sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 65,749 shares — an estimated $1.9M sold.
Bank of America first reported a position in MRSN in Q3 2017 and held it in 34 quarters. The position peaked at $11.1M in Q3 2020. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Bank of America reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 65,749 Mersana Therapeutics shares in Q1 2026, an estimated $1.9M.
- Bank of America first reported a position in Mersana Therapeutics in Q3 2017 and held it in 34 quarters.
- Bank of America's Mersana Therapeutics position peaked at $11.1M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.